Patent: 10,227,328
✉ Email this page to a colleague
Summary for Patent: 10,227,328
Title: | Heterocyclic compound and pharmaceutical composition comprising same |
Abstract: | The present invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc. |
Inventor(s): | Min; Changhee (Daejeon, KR), Oh; Byungkyu (Gyeryong-si, KR), Kim; Yongeun (Daejeon, KR), Park; Changmin (Daejeon, KR) |
Assignee: | BEYONDBIO INC. (Daejeon, KR) |
Application Number: | 15/546,714 |
Patent Claims: | see list of patent claims |
Details for Patent 10,227,328
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2035-02-04 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-02-04 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-02-04 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2035-02-04 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2035-02-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |